PathGroup chooses Proscia for digital pathology

“Taking this next step on our journey requires a company to serve as our trusted partner and a platform that will grow across our network,” said Ben W Davis, MD, CEO of PathGroup. “After a robust evaluation, we are thrilled that Proscia shares our vision for a fully digital future and confident that Concentriq Dx will enable us to rapidly expand upon our existing digital pathology foundation. With Proscia’s nimbleness and speed to innovation, we will leverage the latest technology, including AI, to provide the next generation of diagnosis for millions of patients.”

*Concentriq Dx is CE-marked under IVDR and is available for primary diagnosis in the US during the COVID-19 public health emergency.